NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Universe Pharmaceuticals Inc. UPC
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$17.9B
▼ 22.4% vs FY2024
EPS · FY25
$-8.06
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-7.2%
Net margin · FY25
-20.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 17.9B
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 21 cents on every revenue dollar this year.
Per share
USD -8.06
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-7.2%
Return on equity, FY2025
ROE
Operating margin-16.3%
Net margin-20.6%
Return on assets-5.4%
Each USD of equity lost 7 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+257.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+663.4%
+257.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 69.3B
total assets, end of FY2025
Total assetsUSD 69.3B
EquityUSD 56.1B
CashUSD 33.6B
Gross debtUSD 2.1B
Net debtUSD -31.5B
Current ratio4.07×
The company holds more cash than debt.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
17.9
23.0
32.3
0.0
0.0
0.0
0.0
Operating income $B
−2.9
−8.0
−4.0
−0.0
0.0
0.0
0.0
EBITDA $B
−2.4
−7.5
−3.5
−0.0
0.0
0.0
0.0
Income tax $B
·
0.6
2.3
0.0
0.0
0.0
0.0
Net income $B
−3.7
−8.7
−6.6
−0.0
0.0
0.0
0.0
EPS, diluted $
−8.06
−626.96
−1089.21
−1309.11
3.58
0.47
0.47
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
212
ROE %
−7.2
−23.8
−20.8
−0.0
33.4
45.5
61.0
Shares out B
0.00
0.00
0.02
0.00
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 26
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed